OUR RESEARCH
NASH
Targets & Clinical Progress
Posters/Publications
OUR PIPELINE
Pipeline
Clinical Trials
Expanded Access Policy
OUR STORY
Overview
Management Team
Partnership
NEWS
CAREERS
OUR RESEARCH
NASH
Targets & Clinical Progress
Posters/Publications
OUR PIPELINE
Pipeline
Clinical Trials
Expanded Access Policy
OUR STORY
Overview
Management Team
Partnership
NEWS
CAREERS
Posters/Publications
Title
Venue
Type
Date
Significant lipid lowering by ASC41, an oral tablet, liver-targeted THRβ agonist, in a phase I randomized, double-blind, placebo controlled single- and multiple-ascending dose study
EASL International Liver Congress
poster
04/2021
Significant Improvement of NAFLD Activity Scores and Liver Fibrosis by ASC42, a novel non-steroidal FXR agonist, in High Fat Diet Induced NASH mice
EASL International Liver Congress
poster
04/2021
Significant Improvement of NAFLD Activity Scores and Liver Fibrosis by ASC41, a Selective THR-β Agonist, in High Fat Diet Induced NASH SD Rats
EASL International Liver Congress
poster
04/2021